The Human Variable 

Clinical trials for ME/CFS have consistently failed not because therapies were inherently ineffective, but because the system was never built for conditions like ME/CFS and related IACCs. FDA gold-standard trial design assumes predictable progression, uniform subtypes, and tolerance for interventions — none of which apply to ME/CFS The CYNAERA Thesis asserts that repurposed drugs can work for ME/CFS if trials account for post-exertional malaise (PEM),(MCAS), and POTS

A Nobel-scale leap, built outside the system. This isn’t just another CRISPR project. CYNAERA’s AI-powered gene editing platform was designed by a patient, for patients—modeling remission across millions of synthetic profiles to restore immune stability in infection-associated chronic conditions like Long COVID, ME/CFS, and MCAS. It cuts years off clinical trial timelines. It eliminates $5–10 million in early development costs. It’s scalable and ethical globally. AI meets bio

Infection-associated chronic conditions (IACCs) such as Long COVID, ME/CFS, POTS, and MCAS are not disparate diagnoses — they are systemic sequelae following immune injury. For too long, medicine has treated these illnesses as anomalies or mysteries, when in fact, they follow a biologically predictable pattern of dysregulation.

By harnessing real-time data and predictive analytics, AI frameworks are enabling proactive management of chronic illnesses, which means patients can anticipate flare-ups and adjust their care before symptoms become severe.

Modular intelligence isn’t a trend. The systems that are still standing aren’t the most “powerful.” They’re the ones that can evolve.

Default Logic is the baked-in code, policy, or logic that treats outdated context as static truth. A wrong assumption that costs real money.